

Regeneus

Pipeline expansion

Regeneus has added another project to its portfolio, with licensing of global rights to an autologous human cancer vaccine that is expected to enter the clinic in Q115. Developed at the Kolling Institute, Sydney, the technology was already licensed to Regeneus for veterinary applications (Kvax), which is now in a US marketing trial for osteosarcoma in dogs. Cancer immunotherapy, including multiple approaches to cancer vaccines, is a biotech hotspot and we look forward to progress with Regeneus's new candidate. Our overall valuation is now A\$145m, or A\$0.79 per share.

Year end	Revenue (A\$m)	PBT* (A\$m)	EPS* (A\$)	DPS (A\$)	P/E (x)	Yield (%)
06/12	1.26	(4.95)	(0.03)	0.0	N/A	N/A
06/13	1.81	(7.72)	(0.05)	0.0	N/A	N/A
06/14e	1.97	(9.65)	(0.04)	0.0	N/A	N/A
06/15e	3.47	(10.85)	(0.04)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments. PBT excludes R&D tax rebate.

Option exercised

Regeneus held an option to license global rights to develop the Kolling Institute's cancer vaccine technology for human uses, having secured veterinary rights (developed as Kvax) in January 2013. The decision to exercise this option, with a Phase I safety study to start in Q115, is a positive development given burgeoning interest in the cancer immunotherapy field, although fresh funds will be required. The trial design and target tumour have yet to be confirmed.

Kvax advances in the US

The recent agreement with a US vet health care services group means Kvax can now enter a marketing trial, aimed at treating osteosarcoma in dogs; positive data are important to support commercialising the product in the US. Hennessy Research will manufacture the vaccine, which involves removing a small amount of tumour or biopsy from the dog to produce a personalised (autologous) therapy.

MSC development on track

While the cancer vaccine technology is an increasingly important part of Regeneus's portfolio, the core business and key valuation driver remains its adipose (fat)-derived mesenchymal stem cell (MSC) technology, being developed across multiple areas and geographies. Progenza, an allogeneic (off-the-shelf) MSC product for osteoarthritis, is expected to enter a Phase I/II study in H115.

Valuation: Adjusted to A\$145m, A\$0.79 per share

Including the human cancer vaccine adds A\$5m to our DCF model, based on indicative peak sales of A\$500m, a launch in 2020 and a 10% probability of success. Our overall valuation is now A\$145m (A\$0.79/share) vs A\$141m (A\$0.77/share), after also adjusting for FY14e cash of A\$3.5m (vs A\$6.6m at H114). Even with a A\$3.3m estimated R&D tax rebate in September, fresh funds are required by H115 to support current plans to advance multiple programmes.

Cancer vaccine licence

Pharma & biotech

22 July 2014

Price **A\$0.30**

Market cap **A\$55m**

A\$1.07/US\$

Net cash (A\$m) at December 2013 6.6

Shares in issue 184.4m

Free float 83%

Code RGS

Primary exchange ASX

Secondary exchange N/A

Share price performance



Business description

Regeneus is an Australian biotechnology company marketing and developing mesenchymal stem cell (MSC) products for musculoskeletal conditions in humans and animals. HiQCell (human) and CryoShot (animal), are available commercially in Australia. Progenza (allogeneic, off-the-shelf) will enter a Phase I/IIa study for osteoarthritis in H115.

Next events

HiQCell: commercial launch in Singapore	H214
Progenza: pre-clinical safety data/Phase I/II study design	H214
CryoShot: Australia clinical trial results	H214
Human cancer vaccine: Start Phase I safety study	Q115

Analysts

Christian Glennie	+44 (0)20 3077 5727
Dr Mick Cooper	+44 (0)20 3077 5734

healthcare@edisongroup.com

[Edison profile page](#)

Human cancer vaccine play

Cancer immunotherapy is a broad and burgeoning field, covering a number of classes of agents – vaccines, DC-based vaccines, adoptive T-cell therapies, immune checkpoint inhibitors – and the inherent potential (proven with some approved products) of this approach to treating cancer is vast. Although the bulk of current excitement surrounds the anti-PD-1 immune checkpoint inhibitors, cancer vaccines are likely to become an important component of attacking cancers, particularly in combination with other agents.

A dendritic cell (DC)-based vaccine, Provenge, gained FDA approval in 2010 for the treatment of prostate cancer, the only approved cancer vaccine to date; FY13 sales of Provenge were \$285m, although previous consensus had been >\$1bn. Multiple cancer vaccine types – from whole tumour cell, cell and tumour lysate, tumour antigen, dendritic cell, DNA- and bacterial-derived vaccines – are in development, increasingly in advanced stages of clinical studies.

Autologous cancer vaccination involves the removal of a tumour or biopsy from the ‘patient’ (animal or human) as the source material to produce a personalised vaccine, which stimulates the immune system to see cancer cells as foreign, prompting immune cells, particularly T-cells, to attack the tumour cells.

Rights secured

Through an agreement with Northern Sydney Local Health District (NSLHD), Regeneus now holds exclusive worldwide rights to develop and commercialise an autologous human cancer vaccine. The technology was developed at the Bill Walsh Translational Cancer Research Laboratory, which is part of the Kolling Institute of Medical Research at Royal North Shore Hospital in Sydney. This candidate is a whole tumour cell-derived vaccine, based on tumour lysate (protein) coupled with an adjuvant, streptavidin, to help stimulate a T-cell response.

Regeneus did not pay any upfront fee, but will be required to pay royalties (4-7% on gross sales) to NSLHD on commercialisation of the product.

Regeneus already held rights to the programme for veterinary applications. Recently published research¹, in a rat model of glioma and a safety study in 25 dogs, produced encouraging results for the streptavidin (immunostimulant)-based vaccine. Rats receiving two vaccinations demonstrated a significant ($p < 0.05$) survival advantage compared with controls (streptavidin only), and also led to remission rates of 30-60% in the aggressive 9L glioma model. Use of Kvac in dogs, which presented to veterinary clinics in Sydney with a range of cancer types (melanoma to bone cancer), showed no adverse reactions and 63% (7/11) of diseased dogs survived longer than would otherwise be expected (based on tumour grade, histology and/or oncology report).

Progressing to the clinic

Regeneus plans to initiate a first-in-man Phase I safety study in Q115, while funding further research at the Bill Walsh Cancer Research Lab. Professor Stephen Clarke and Associate Professor Nick Pavlakis, from the University of Sydney’s Northern Clinical School at the Kolling Institute, will be the investigators on the trial.

The trial design and tumour target have yet to be confirmed, although as a safety study using an experimental treatment, tumours that have limited treatment options and/or an aggressive disease progression are the most likely targets. The primary aim would be to generate safety data, some indication of immune activation and perhaps a tentative insight into efficacy.

1 Weir C et al (2014). Streptavidin: A novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. *Cancer Immunology Research*. Published OnlineFirst 21 [February 2014](#).

Assuming an acceptable safety profile, subsequent studies may look to introduce the vaccine at an earlier stage of disease progression, which is increasingly viewed as a more optimum time for an effective immune response to be stimulated, particularly if used in combination with other agents.

Kvax advances

Regeneus recently entered into an agreement with a US vet health care services group to conduct a marketing trial in the US with Kvax, the company's autologous canine cancer vaccine. This is the same cancer vaccine technology developed by the Kolling Institute.

The trial will be conducted at two US sites and will test two doses of Kvax in treating osteosarcoma in approximately 20 dogs. Progression-free survival and overall survival times will be the primary assessment measures. Hennessy Research will manufacture the vaccine for the US market, including this study and subsequent commercialisation.

The results of the marketing trial are therefore important in supporting full commercialisation in the US. In November 2013, Regeneus received confirmation from the Center for Veterinary Biologics at the US Department of Agriculture that it can commercialise this product in the US.

MSC development continues

Although the cancer vaccine technology is an increasingly important part of Regeneus' portfolio, the core business and key valuation driver remains its adipose (fat) -derived mesenchymal stem cell (MSC) technology. MSCs, for human and veterinary applications, are being developed across multiple areas and geographies.

Progenza, an allogeneic (off-the-shelf) MSC product for osteoarthritis (OA) is expected to enter a Phase I/II study in H115. In April 2014, Regeneus received ethics approval in Australia to collect stem cells from human donors to produce the Progenza product for a clinical study in human volunteers with knee OA. This product could hold significant long-term potential, so progress is important in building up the value of Regeneus's portfolio.

Meanwhile HiQCell, an autologous MSC product available in Australia for musculoskeletal disorders (including OA), has also shown promise as a potential treatment option for chronic neuropathic pain. Results from an open-label study² in 10 patients with persistent, severe and intolerable pain in the face and dental region showed significant reductions in pain intensity scores and in using pain medication.

The results from this study highlight the potential versatility of Regeneus's MSCs, beyond the current focus on musculoskeletal conditions.

Valuation

Including the human cancer vaccine adds A\$5m to our DCF model, based on indicative peak sales of A\$500m, a launch in 2020 and a 10% probability of success. Our overall valuation is now A\$145m (A\$0.79/share) vs A\$141m (A\$0.77/share), after also adjusting for FY14e cash of A\$3.5m (vs A\$6.6m at H114). Our sum-of-the-parts DCF model is summarised in Exhibit 1 and our key assumptions are displayed in Exhibit 2.

2 Vickers ER, Karsten E, Flood J, and Lilischkis R. A preliminary report on stem cell therapy for neuropathic pain in humans. *Journal of Pain Research* 2014;7 [255–263](#).

Exhibit 1: Regeneus valuation model

Product	Setting	Region	Status	Launch	NPV (A\$m)	Peak sales (A\$m)	Probability of success	Economic interest	rNPV (A\$m)	rNPV per share (A\$)
HiQCell	Human – OA (knee/hip surgeries)	Australia	Marketed	2011	24.2	17	75%-100%	Operating profit (40%-60%)	18.4	0.10
HiQCell	Human – OA (knee/hip surgeries)	Singapore	Registration	2014	1.6	4	75%	30% effective royalty rate	1.1	0.01
HiQCell	Human – OA (knee/hip surgeries)	Germany	Registration	2015	16.8	26	65%	30% effective royalty rate	10.6	0.06
Progenza	Human – OA	Australia / Japan / EU / US	Phase IIa (planned)	2018 (Japan); 2020 (Aus); 2021 (EU/US)	328.1	1,526	15%	Royalty (15%)	43.9	0.24
CryoShot	Animal – OA	Australia	Pre-registration	2012	9.6	6	75%-100%	Operating profit (40%-60%)	7.2	0.04
CryoShot	Animal – OA	EU	Registration studies	2017	28.7	45	65%	30% effective royalty rate	18.2	0.10
CryoShot	Animal – OA	US	Registration studies	2017	30.9	54	65%	30% effective royalty rate	19.7	0.11
CryoShot	Animal – OA	Japan	Registration studies	2016	4.0	10	65%	30% effective royalty rate	2.2	0.01
Kvax canine vaccine	Dog cancer	WW	Marketing studies	2016	32.6	37	50%	30% effective royalty rate	15.6	0.08
Human cancer vaccine	Solid tumours	WW	Phase I-ready	2020	78.5	500	10%	13% net royalties	4.9	0.03
Portfolio total					554.9				141.8	0.77
Cash (FY14e)									3.5	0.02
Overall valuation									145.3	0.79

Source: Edison Investment Research

Exhibit 2: Regeneus valuation model assumptions

Product	Setting	Region	Status	Launch	Key assumptions
HiQCell	Human – OA (knee/hip surgeries)	Australia	Marketed	2011	Knee/hip surgeries used as a proxy for market opportunity; 45,000 knee surgeries (5% HiQCell peak penetration) + 36,000 hip surgeries (5% HiQCell peak penetration); current use mainly knee (66%) vs hip (10%); A\$4,800 per procedure (includes cryo preservation fee and repeat doses); peak sales in 2025; sliding scale of probability (100% near term to 75% post-2020).
HiQCell	Human – OA	Singapore	Registration	2014	1,000 PRP procedures/year (used as a proxy for market opportunity); 50% due to OA; 25% HiQCell peak penetration.
HiQCell	Human – OA	Germany	Registration	2015	Knee/hip surgeries used as a proxy for market opportunity; 175,000 knee surgeries (2% HiQCell peak penetration in 2021) + 245,000 hip surgeries (1% HiQCell peak penetration); equivalent A\$5,000 per procedure (includes cryo preservation fee and repeat doses); peak sales in 2021, then replaced by Progenza.
Progenza	Human – OA	WW	Phase IIa (planned)	2018 - 2021	Prevalence ~10% of >55yrs in all regions; 10% severe (grade 3+) OA requiring treatment; 5% Progenza peak market share (2025; six yrs to peak); A\$10,000 per procedure (A\$7,500 in EU).
CryoShot	Animal – OA	Australia	Pre-registration	2012	~4,500 small animal vet practitioners; peak penetration in 2021, with 5% use CryoShot, 75x per year, at A\$250 per dose; sliding scale of probability (100% near term to 75% post-2020).
CryoShot	Animal – OA	EU	Registration studies	2017	~90,000 small animal vet practitioners; peak penetration in 2025, with 3% use CryoShot, 50x per year, at A\$250 per dose; 65% probability with studies/partners to complete.
CryoShot	Animal – OA	US	Registration studies	2017	~50,000 small animal vet practitioners; peak penetration in 2025, with 5% use CryoShot, 75x per year, at A\$250 per dose; 65% probability with studies/partners to complete.
CryoShot	Animal – OA	Japan	Registration studies	2016	~14,000 small animal vet practitioners; peak penetration in 2025, with 3% use CryoShot, 75x per year, at A\$250 per dose; 65% probability with studies/partners to complete.
Kvax canine vaccine	Dog cancer	WW	Marketing studies	2016	~175/100,000 annual incidence of dog cancers; ~280,000 cancers US/EU/Japan/Aus; assume 33% get drug/vaccine treatment; 25% peak Kvax penetration of treated dogs by 2021 (=18,500 doses of Kvax); A\$2,000/treatment course; 50% probability with studies/partners to complete.
Human cancer vaccine	Solid tumours	WW	Phase I-ready	2020	\$500m peak sales indicative potential (non-cancer specific); 13% net royalty rate after 4%-7% pay-away to Northern Sydney Local Health District (NSLHD).

Source: Edison Investment Research

Sensitivities

The stock-specific sensitivities relate to Regeneus's current plan to commercialise certain products in Australia and Singapore (and potentially other territories), which adds an element of execution risk given the investment in infrastructure required. We have assumed timely clinical and commercial progress for multiple programmes across several regions, which should be achievable, but any delays/setbacks would have a negative impact on our valuation.

Development/commercialisation/distribution partners will need to be secured in multiple territories to enable the roll-out of these products. Regeneus has submitted patent applications to cover a range of current and future products, but these have yet to be granted. This adds an element of risk, particularly in relation to certain autologous products, which can be developed by medical and veterinary specialists.

Financials

Regeneus recorded A\$0.49m in revenues for fiscal Q314 (January-March 2014), or A\$1.3m for the first nine months of 2014. Regeneus noted that revenues (mainly from HiQCell and CryoShot procedures in Australia) during Q314 were slower than expected over the Christmas holiday period. We have therefore reduced our total revenue forecast for FY14 to A\$1.97m, vs A\$2.64m previously.

We estimate that Regeneus ended FY14 (30 June 2014) with A\$3.5m in cash, compared to A\$6.6m as of H114 (31 December 2013). Under the Australian government's R&D tax incentive scheme, which effectively reimburses 45% of eligible R&D costs, Regeneus expects to receive A\$3.3m in a lump-sum tax rebate in September. Nevertheless, based on projected sales and operating expenses, our financial model indicates a financing requirement in fiscal H115, and we have nominally attributed A\$10m to long-term debt, as per our standard policy.

Regeneus plans to advance an extensive product portfolio across multiple geographies and as such, some prioritisation of projects may be a natural outcome as the company assesses its financing options.

Exhibit 3: Financial summary

	A\$000s	2012	2013	2014e	2015e	2016e
Year-end 30 June		AASB	AASB	AASB	AASB	AASB
PROFIT & LOSS						
Revenue		1,262	1,812	1,968	3,473	8,937
Cost of Sales		(246)	(581)	(668)	(1,106)	(1,731)
Gross Profit		1,016	1,232	1,300	2,367	7,206
R&D expenses		(3,212)	(4,134)	(5,375)	(6,719)	(7,726)
SG&A expenses		(2,828)	(4,549)	(5,503)	(6,530)	(7,576)
EBITDA		(4,910)	(7,256)	(9,385)	(10,658)	(7,782)
Operating Profit (before GW and except.)		(5,017)	(7,437)	(9,568)	(10,869)	(8,080)
Intangible Amortisation		(6)	(15)	(10)	(12)	(16)
Exceptionals		0	0	0	0	0
Other		11	208	86	0	0
Operating Profit		(5,012)	(7,244)	(9,492)	(10,881)	(8,096)
Net Interest		72	(278)	(81)	18	44
Profit Before Tax (norm)		(4,945)	(7,715)	(9,649)	(10,851)	(8,036)
Profit Before Tax (FRS 3)		(4,940)	(7,522)	(9,573)	(10,864)	(8,052)
Tax benefit		1,679	2,327	3,300	3,023	3,477
Profit After Tax (norm)		(3,266)	(5,388)	(6,349)	(7,828)	(4,559)
Profit After Tax (FRS 3)		(3,261)	(5,195)	(6,273)	(7,840)	(4,576)
Average Number of Shares Outstanding (m)		102.9	102.9	149.4	184.5	185.5
EPS - normalised (A\$)		(0.03)	(0.05)	(0.04)	(0.04)	(0.02)
EPS - FRS 3 (A\$)		(0.03)	(0.05)	(0.04)	(0.04)	(0.02)
Dividend per share (A\$)		0.0	0.0	0.0	0.0	0.0
BALANCE SHEET						
Fixed Assets		572	653	1,940	2,249	2,867
Intangible Assets		45	45	44	65	87
Tangible Assets		527	609	705	993	1,589
Investments		0	0	1,191	1,191	1,191
Current Assets		2,724	3,370	8,262	10,528	5,771
Stocks		143	231	311	515	806
Debtors		107	27	112	112	112
Cash		528	534	3,500	5,839	338
Other		1,946	2,579	4,339	4,062	4,515
Current Liabilities		(1,348)	(6,892)	(1,138)	(1,138)	(1,138)
Creditors		(1,294)	(1,842)	(997)	(997)	(997)
Short term borrowings		0	(4,900)	0	0	0
Other		(53)	(150)	(141)	(141)	(141)
Long Term Liabilities		0	0	0	(10,000)	(10,000)
Long term borrowings		0	0	0	(10,000)	(10,000)
Other long term liabilities		0	0	0	0	0
Net Assets		1,949	(2,869)	9,063	1,639	(2,500)
CASH FLOW						
Operating Cash Flow		(2,940)	(4,618)	(6,804)	(7,106)	(4,569)
Net Interest		0	0	0	0	0
Tax		0	0	0	0	0
Capex		(421)	(277)	(307)	(555)	(932)
Acquisitions/disposals		0	0	0	0	0
Financing		2,300	0	10,077	0	0
Dividends		0	0	0	0	0
Other		0	0	4,900	0	0
Net Cash Flow		(1,062)	(4,895)	7,867	(7,661)	(5,502)
Opening net debt/(cash)		(1,590)	(528)	4,366	(3,500)	4,161
HP finance leases initiated		0	0	0	0	0
Other		0	0	0	0	0
Closing net debt/(cash)		(528)	4,366	(3,500)	4,161	9,662

Source: Regeneus accounts, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Regeneus and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2014. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.